Cargando…

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

In 30–50% of patients with metastatic non-medullary thyroid cancer the metastases are not radioiodine-avid and so there is no effective treatment. Retinoids have demonstrated inhibition of thyroid tumor growth and induction of radioiodine uptake. The aim of our study was to assess benefits of the re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Handkiewicz-Junak, Daria, Roskosz, Jozef, Hasse-Lazar, Kornelia, Szpak-Ulczok, Sylwia, Puch, Zbigniew, Kukulska, Aleksandra, Olczyk, Tomasz, Piela, Andrzej, Paliczka-Cieslik, Ewa, Jarzab, Barbara
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739165/ https://www.ncbi.nlm.nih.gov/pubmed/19646277 http://dx.doi.org/10.1186/1756-6614-2-8

Ejemplares similares

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer
por: Ledwon, Aleksandra, et al.
Publicado: (2021)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma
por: Kukulska, Aleksandra, et al.
Publicado: (2019)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer
por: Kukulska, Aleksandra, et al.
Publicado: (2021)

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level
por: Jarzab, Barbara, et al.
Publicado: (2013)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
por: Pacini, Furio, et al.
Publicado: (2021)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma
por: Zagar, Ivana, et al.
Publicado: (2012)

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment
por: Cho, Bo Youn, et al.
Publicado: (1990)

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
por: Gawlik, Tomasz, et al.
Publicado: (2010)

Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy
por: Park, Hee Jeong, et al.
Publicado: (2017)

Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled ”European comments to ATA medullary thyroid cancer guidelines”
por: Jarząb, Barbara, et al.
Publicado: (2013)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Tracheal Obstruction by an Invading Well-Differentiated Thyroid Carcinoma
por: Pontikides, Nickolaos, et al.
Publicado: (2013)

Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2022)

Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease
por: Kim, Jinyoung, et al.
Publicado: (2021)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2013)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012)

Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma
por: Pfeifer, Aleksandra, et al.
Publicado: (2019)

9-cis retinoic acid induces neurorepair in stroke brain
por: Yu, Seong-Jin, et al.
Publicado: (2017)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
por: Damle, Nishikant, et al.
Publicado: (2011)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

Gene signature of the post-Chernobyl papillary thyroid cancer
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2016)

Monoclonal Antibodies to the Thyrotropin Receptor
por: Ando, Takao, et al.
Publicado: (2005)

Circulating thyrotropin is upregulated by estradiol
por: Benvenga, Salvatore, et al.
Publicado: (2018)

Thyrotropin Receptor Blocking Antibodies
por: Diana, Tanja, et al.
Publicado: (2018)

GATA2 Mediates Thyrotropin-Releasing Hormone-Induced Transcriptional Activation of the Thyrotropin β Gene
por: Ohba, Kenji, et al.
Publicado: (2011)

Multiple Thyrotropin β-Subunit and Thyrotropin Receptor-Related Genes Arose during Vertebrate Evolution
por: Maugars, Gersende, et al.
Publicado: (2014)

Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.
por: Formelli, F., et al.
Publicado: (1997)

Metabolomics research on potential role for 9‐cis‐retinoic acid in breast cancer progression
por: Wu, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_upkqcsk3ta6ph4s3po8s05fj7b